Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions

Blood (2015) 126 (23): 496.

https://doi.org/10.1182/blood.V126.23.496.496

Published: 2015

Journal Articles

Obinutuzumab (GA101) Plus CHOP Or FC In Relapsed/Refractory Follicular Lymphoma: Final Data From The Maintenance Phase Of The Phase 1b GAUDI Study (BO21000)

Andrew Davies, MRCP, PhD, John Radford, MD, Guillaume Cartron, MD, PhD, Franck Morschhauser, MD, PhD, Gilles Andre Salles, MD, PhD, Robert Marcus, MB, FRCP, FRCPath, Michael K Wenger, MD, Guiyuan Lei, PhD, Elisabeth Wassner-Fritsch, PharmD, Umberto Vitolo, MD

Blood (2013) 122 (21): 1814.

https://doi.org/10.1182/blood.V122.21.1814.1814

Published: 2013

Journal Articles

Telomere Length and Treatment Outcome In Chronic Lymphocytic Leukemia: Results From The CLL8 Trial

Billy Michael Chelliah Jebaraj, PhD, Raymonde Busch, PhD, Thorsten Zenz, MD, Andreas Bühler, MD, Dirk Winkler, MD, Andrea Schnaiter, MD, Jennifer Edelmann, MD, Daniel Mertens, PhD, Sebastian Böttcher, MD, Michael Kneba, MD, Ulrich Jäger, MD, Michael K Wenger, MD, Guenter Fingerle-Rowson, MD PhD, Clemens Wendtner, MD, Anna-Maria Fink, MD, Kirsten Fischer, MD, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2013) 122 (21): 671.

https://doi.org/10.1182/blood.V122.21.671.671

Published: 2013

Journal Articles

Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results Of The CLL11 Trial

Blood (2013) 122 (21): 6.

https://doi.org/10.1182/blood.V122.21.6.6

Published: 2013

Journal Articles

Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000)

Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Andrew Grigg, MBBS, FRACP, FRCPA, Marcos González, Martin Dreyling, Simon A. Rule, MD, Guiyuan Lei, Elisabeth Wassner-Fritsch, Michael K. Wenger, MD, Paula Marlton, MBBS, FRACP, FRCPA

Blood (2012) 120 (21): 3686.

https://doi.org/10.1182/blood.V120.21.3686.3686

Published: 2012

Journal Articles

Prognostic Impact of Biallelic Versus Monoallelic Deletion 13q and the Proportion of Cells with Deletion 13q within the CLL8 Trial of the German CLL Study Group (GCLLSG)

Dirk Winkler, MD, Raymonde Busch, Andreas Buehler, MD, Michael K. Wenger, MD, Kirsten Fischer, MD, Anna-Maria Fink, MD, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2011) 118 (21): 2841.

https://doi.org/10.1182/blood.V118.21.2841.2841

Published: 2011

Journal Articles

Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG)

Anna Fink, MD, Raymonde Busch, Natali Pflug, MD, Sebastian Boettcher, MD, Dirk Winkler, MD, Andreas Buehler, MD, Matthias Ritgen, MD, Kirsten Fischer, MD, Barbara Eichhorst, MD, Clemens-Martin Wendtner, MD, Myriam Mendila, MD, Michael K. Wenger, MD, Hartmut Doehner, MD, Michael Kneba, MD, Stephan Stilgenbauer, MD, Michael Hallek, MD

Blood (2011) 118 (21): 977.

https://doi.org/10.1182/blood.V118.21.977.977

Published: 2011

Journal Articles

Efficacy and Safety of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma: Results From a Phase I/II Study (BO20999)

Gilles Andre Salles, Franck Morschhauser, MD, PhD, Catherine Thieblemont, MD, Philippe Solal-Celigny, Thierry Lamy, MD, PhD, Herve Tilly, Pierre Feugier, MD, PhD, Steven Le Gouill, MD, PhD, Emmanuel Gyan, MD, PhD, Reda Bouabdallah, MD, Michael K. Wenger, MD, Elisabeth Wassner-Fritsch, Elina Asikanius, Guillaume Cartron, MD, PhD

Blood (2011) 118 (21): 268.

https://doi.org/10.1182/blood.V118.21.268.268

Published: 2011

Journal Articles

Minimal Residual Disease (MRD) Re-Growth Kinetics Are An Independent Predictor for Progression Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) and Are Related to Biologically Defined CLL-Subgroups– Results From the CLL8 Trial of the German CLL Study Group (GCLLSG)

Sebastian Boettcher, MD, Matthias Ritgen, MD, Kirsten Fischer, MD, Stephan Stilgenbauer, MD, Raymonde Busch, Gunter R. Fingerle-Rowson, MD, PhD, Anna-Maria Fink, MD, Andreas Buehler, MD, Dirk Winkler, MD, Michael K. Wenger, MD, Myriam Mendila, MD, Clemens Wendtner, MD, Barbara Eichhorst, MD, Hartmut Döhner, MD, Michael Hallek, MD, Michael Kneba, MD

Blood (2011) 118 (21): 1777.

https://doi.org/10.1182/blood.V118.21.1777.1777

Published: 2011

Journal Articles

Comparison of Single Agent GA101 In Japanese and European Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL) – Results From Two Phase I Studies

Michinori Ogura, MD, PhD, Franck Morschhauser, MD, PhD, Kensei Tobinai, MD, PhD, Guillaume Cartron, MD, PhD, Kiyohiko Hatake, MD, PhD, Michael K. Wenger, MD, Joe Birkett, PhD, Naoko Oya, Kiyomi Nishima, Gilles Salles, MD, PhD

Blood (2010) 116 (21): 4921.

https://doi.org/10.1182/blood.V116.21.4921.4921

Published: 2010

Journal Articles

Pharmacokinetics of RO5072759 (GA101) In Patients with Relapsed/Refractory CD20 + Malignant Disease (Phase I/II Study BO20999)

Georgina Meneses-Lorente, PhD, David Carlile, PhD, Joe Birkett, PhD, Michael K. Wenger, MD, Guillaume Cartron, MD, PhD, Franck Morschhauser, MD, PhD, Gilles Andre Salles, MD, PhD

Blood (2010) 116 (21): 1833.

https://doi.org/10.1182/blood.V116.21.1833.1833

Published: 2010

Journal Articles

Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients – First Results From a Phase II Study In Patients with Relapsed/Refractory DLBCL and MCL

Guillaume Cartron, MD, PhD, Catherine Thieblemont, MD, PhD, Philippe Solal-Celigny, MD, Franck Morschhhauser, MD, PhD, Corinne Haioun, MD, Reda Bouabdallah, MD, Thierry Lamy, MD, PhD, Noel Milpied, MD, Steven Le Gouill, MD, Pierre Feugier, MD, PhD, Joe Birkett, PhD, Michael K. Wenger, MD, Elina Asikanius, Gilles Salles

Blood (2010) 116 (21): 2878.

https://doi.org/10.1182/blood.V116.21.2878.2878

Published: 2010

Journal Articles

Higher Doses of Rituximab May Be Required for Patients with CLL as Compared to NHL Based On Population Pharmacokinetic (PK) Modeling.

Jing Li, Ph.D., Jianguo Zhi, Ph.D., Michael K. Wenger, MD, Nancy Valente, MD, Jennifer Visich, Ph.D.

Blood (2009) 114 (22): 1742.

https://doi.org/10.1182/blood.V114.22.1742.1742

Published: 2009

Journal Articles

FC-Gamma Receptor (FCGR) 2A and 3A Polymorphisms Do Not Influence the Outcome of Relapsed or Refractory CLL Patients Treated with Rituximab, Fludarabine, and Cyclophosphamide (R-FC) or Fludarabine, and Cyclophosphamide (FC) Alone.

David Dornan, Ph.D, Olivia Spleiss, Ph.D, Ru-Fang T Yeh, PhD, Guillemette Duchateau-Nguyen, PhD, Tadeusz Robak, Sergey I Moiseev, MD, Anna Dmoszynska, MD, Philippe Solal-Celigny, MD, Krzysztof Warzocha, MD, PhD, Javier Loscertales, MD, John Catalano, MD, Boris V Afanasiev, MD, Loree Larratt, MD, Viktor A Rossiev, MD, PhD, Isabelle Bence-Bruckler, MD, FRCPC, Christian H. Geisler, MD, DMSc, Marco Montillo, MD, Michael K. Wenger, MD, Martin Weisser, MD

Blood (2009) 114 (22): 2338.

https://doi.org/10.1182/blood.V114.22.2338.2338

Published: 2009

Journal Articles

Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial

Tadeusz Robak, MD, PhD, Sergey I Moiseev, MD, Anna Dmoszynska, MD, Philippe Solal-Céligny, MD, Krzysztof Warzocha, MD, PhD, Javier Loscertales, MD, John Catalano, MD, Boris V Afanasiev, MD, Loree Larratt, MD, Christian Geisler, MD, DMSc, Marco Montillo, MD, Peter Ganly, BMBCh, PhD, Caroline Dartigeas, MD, András Rosta, MD, PhD, Ann Janssens, MD, Myriam Mendila, MD, Jörg Maurer, Michael K. Wenger, MD

Blood (2008) 112 (11): lba-1.

https://doi.org/10.1182/blood.V112.11.lba-1.lba-1

Published: 2008

Journal Articles

The MAXIMA Study: Safety of Rituximab (MabThera®) Maintenance Therapy in Patients with Follicular Non-Hodgkin’s Lymphoma Who Have Responded to Induction Therapy.

Michael K. Wenger, MD, Robin Foa, MD, Luca Arcaini, MD, Andrej Vranovský, MD, Valentina Ivanova, MD, Van Hazel Guy, MD, Sabira Kurtovic, MD, Soledad Durán, MD, Stephen McKechnie, Daniel Thurley, MD

Blood (2007) 110 (11): 4475.

https://doi.org/10.1182/blood.V110.11.4475.4475

Published: 2007

Journal Articles

Serum Levels and Pharmacokinetic of Rituximab in Bi-Weekly R-CHOP in Elderly Patients with DLBCL Treated in the RICOVER-60 Trial.

Marcel Reiser, MD, Michael K. Wenger, MD, Christina Nickenig, MD, N. Peter, MD, Christian Kuhn, MD, Bernd Metzner, MD, Martin Theisohn, MD, Michael Pfreundschuh, MD

Blood (2006) 108 (11): 2748.

https://doi.org/10.1182/blood.V108.11.2748.2748

Published: 2006

Journal Articles

Rituximab during Pregnancy: Serum Levels, B Cell Counts and Immunoglobulin Levels in Mother and Child.

Birte Friedrichs, MD, Markus Tiemann, MD, Michael K. Wenger, MD, Karl Verpoort, MD, Norbert Schmitz, MD

Blood (2005) 106 (11): 1508.

https://doi.org/10.1182/blood.V106.11.1508.1508

Published: 2005

NARROW

Obinutuzumab (GA101) Plus CHOP Or FC In Relapsed/Refractory Follicular Lymphoma: Final Data From The Maintenance Phase Of The Phase 1b GAUDI Study (BO21000)

Telomere Length and Treatment Outcome In Chronic Lymphocytic Leukemia: Results From The CLL8 Trial

Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results Of The CLL11 Trial

Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000)

Prognostic Impact of Biallelic Versus Monoallelic Deletion 13q and the Proportion of Cells with Deletion 13q within the CLL8 Trial of the German CLL Study Group (GCLLSG)

Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG)

Efficacy and Safety of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma: Results From a Phase I/II Study (BO20999)

Minimal Residual Disease (MRD) Re-Growth Kinetics Are An Independent Predictor for Progression Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) and Are Related to Biologically Defined CLL-Subgroups– Results From the CLL8 Trial of the German CLL Study Group (GCLLSG)

Comparison of Single Agent GA101 In Japanese and European Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL) – Results From Two Phase I Studies

Pharmacokinetics of RO5072759 (GA101) In Patients with Relapsed/Refractory CD20 + Malignant Disease (Phase I/II Study BO20999)

Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients – First Results From a Phase II Study In Patients with Relapsed/Refractory DLBCL and MCL

Higher Doses of Rituximab May Be Required for Patients with CLL as Compared to NHL Based On Population Pharmacokinetic (PK) Modeling.

FC-Gamma Receptor (FCGR) 2A and 3A Polymorphisms Do Not Influence the Outcome of Relapsed or Refractory CLL Patients Treated with Rituximab, Fludarabine, and Cyclophosphamide (R-FC) or Fludarabine, and Cyclophosphamide (FC) Alone.

Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial

The MAXIMA Study: Safety of Rituximab (MabThera®) Maintenance Therapy in Patients with Follicular Non-Hodgkin’s Lymphoma Who Have Responded to Induction Therapy.

Serum Levels and Pharmacokinetic of Rituximab in Bi-Weekly R-CHOP in Elderly Patients with DLBCL Treated in the RICOVER-60 Trial.

Rituximab during Pregnancy: Serum Levels, B Cell Counts and Immunoglobulin Levels in Mother and Child.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only